Compare DexCom, Inc. (DXCM) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Williams Companies Inc — how do they compare? DexCom, Inc. trades at $89.26 (market cap $33.79B), while Williams Companies Inc trades at $73.65 (market cap $88.45B). The key difference: Williams Companies Inc is far larger — about 2.6× DexCom, Inc.'s market cap, and Williams Companies Inc pays a 2.9% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | WMB | |
|---|---|---|
Market Cap | $33.79B | $88.45B |
Sector | Health | Energy |
52-Week High | $89.53 | $79.40 |
52-Week Low | $54.84 | $56.51 |
Enterprise Value | $33.24B | $119.07B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Williams Companies (WMB) trades at $71.85, up 2.06% today, with a neutral technical signal and mixed earnings history. The company reported Q2 2026 EPS of $0.50, slightly missing estimates, but raised full-year EBITDA guidance. Recent news highlights the $5.5 billion acquisition of Momentum Midstream, enhancing its Gulf Coast presence and supporting long-term growth targets. Financials show strong profitability with a 25.18% net income margin and robust cash flow from operations of $5.90 billion in 2025.
Outlook remains positive with analyst consensus favoring Buy ratings (79.41%) and a $87.14 price target, though risks include execution of acquisitions and debt levels. The stock offers a dividend yield supported by stable cash flows, positioning it for growth in energy infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
